New Products and Industry News

Mild cleansing perineal cloth helps control odor

    Coloplast Corp. Skin Health Division (Marietta, Ga) introduces the Baza Cleanse and Protect® Perineal Cloth with Odor Control, the latest addition to the Baza Cleanse and Protect product line of 3-in-1 lotions that cleanse, moisturize, and protect the skin from the effects of incontinence.

    The new perineal cloth incorporates an odor-control lotion that absorbs 30% more and delivers twice as much protectant than the market-leading product.

    The cloth cleanses with mild, pH-balanced, no-rinse surfactants. The cloth contains rich emollients and humectants to condition the skin and dimethicone to protect the skin.

    For more information call (800) 533-0464.

Slimmer design for suspension boots features increased comfort, ease of use

    DM System’s (Evanston, Ill) new Heelift® design includes extended stitching along the top rim of the boot to narrow the forefoot, creating a slimmer, less bulky profile that is more comfortable for the patient. This feature increases forefoot support to improve protection against foot drop, equinus deformity, and heel cord contracture. In addition, the extended stitching reduces the possibility of the foam tearing through the ventilation holes by eliminating the stress risers in that area of the boot.

    The redesigned boot features one-handed closure. Two non-abrasive soft straps with D-ring closures have replaced the previous multistrap configuration. The simplified strap design permits easier adjustment of the strap tension, making application of the boot easier and quicker.

    The boot eliminates pressure from the heel, lifting it with an elevation pad and suspending it in protective space. Pressure is transferred from the heel to the lower leg. In prevention regimens, the boot can be used with patients who are immobile, postoperative, or suffer from diabetes, cardiovascular disease, or dietary deficiencies. It is ideal in cases of foot drop, flaccid paralysis (non-spastic), pre- and postoperative hip fractures, and skin grafts.

    For more information, call (800) 254-5438.

Wound dressings approved for sale in Canada

    Covalon (Mississauga, Ontario) has received Health Canada Therapeutic Products Directorate Medical Device licenses for three products: ColActive Collagen™ wound dressing, ColActive Ag™ antimicrobial collagen wound dressing, and CovaClear Ag™ antimicrobial collagen/hydrogel wound dressing.

    The company can now expand sales by entering the Canadian acute and chronic care markets, with an increased product offering across a greater range of treatment indications including: pressure ulcers, diabetic ulcers, ulcers caused by mixed vascular etiologies, venous ulcers, first- and second-degree burns, donor and graft sites, abrasions and lacerations, dehisced surgical wounds, and traumatic wounds healing by secondary intention.

    For more information, visit www.covalon.com or call (905) 568-8400.

Biotech company receives FDA approval to begin phase I clinical trials for urinary incontinence drug

    Enhance Biotech Inc. (Durham, NC) a specialty pharmaceutical company that acquires, develops, and seeks to commercialize drugs primarily in the lifestyle drug market, has received US Food and Drug Administration (FDA) clearance to proceed with Phase I clinical trials for its propriety selective delta agonist, DPI-221, for urge and mixed urinary incontinence (UI). The trial is planned to begin early in 2006.

    Urinary incontinence is comprised primarily of three subtypes—urge incontinence, stress incontinence, and mixed incontinence. The target condition for the DPI-221 compound is urge and mixed incontinence. With this condition, the patient cannot appropriately control the emptying of the bladder appropriately after the recognition of the need to urinate.